Skip to content
Information Technology, Medical Health Aged Care

Sleep tight: New wearable sensor sheds light on getting the best rest

Monash University 2 mins read

In a world first, a new wearable device developed by Monash University researchers will help to record the impact of artificial light on our bodies for sound sleep,  improved mental wellbeing and treating chronic health conditions. 

 

The ‘MiEye’ sensor is the brainchild of circadian biology experts Professor Sean Cain (Adjunct) and Associate Professor Andrew Phillips (Adjunct) from the Faculty of Medicine, Nursing and Health Sciences. 

 

Professor Jon McCormack, Elliott Wilson and Dr Rowan Page from SensiLab – a joint lab between the Faculty of Information Technology and the Faculty of Art, Design and Architecture – worked on making the MiEye device wearable and adapted it for commercial production. 

 

When worn, the device, which senses light over 11 channels and is about as big as a 20-cent piece, records the impact of any light source, such as fluorescent light, overhead LED, sunsets, phone light and device light on the wearer. It then sends feedback to a smartphone application, which calculates the impact of ambient light on our body clock.

 

Research lead Professor Sean Cain said our light behaviour is fundamental to all aspects of our health. 

 

“By providing feedback on light environments, we are trying to make people more conscious of their exposure to different types of light and guide them towards healthier light exposure patterns,” Professor Cain said. 

 

“By helping to manage circadian rhythms, MiEye will be a powerful clinical tool that can aid in the treatment of type 2 diabetes, mental health issues, cardiovascular disease and hypertension, and generally improve health and longevity.”

 

The MiEye sensor has been developed for public use by Circadian Health Innovations – a spin-off company founded by the lead researchers of the project. 

 

Circadian Health Innovations Co-Founder and Chief Technology Officer Associate Professor Andrew Phillips said the device is currently available to select researchers and will be more widely available to clinicians and researchers in 2025.

 

“Ultimately we aim to have the device available to the public where people can use it to get real-time feedback and understand as well as manage their exposure to different types of light. This can be especially useful for travellers suffering from jet lag and shift workers,” Associate Professor Phillips said. 

 

In its development stage, the MiEye sensor won a prestigious Australian Good Design award in 2022 under the ‘Design Research’ category. 

 

“For it to be a feasible wearable device, we designed MiEye to be as compact and light as possible while still incorporating the required sensors from the technological point of view,” SensiLab Engineer, Elliott Wilson said. 

 

Research for the MiEye project was funded by the Monash Institute of Medical Engineering and commercialisation was made possible through Monash Innovation.

 

“This new device is a shining example of synergy between quality research and enterprise to produce tangible health outcomes and positively impact communities,” Monash Innovation Chief Commercialisation Officer Dr Alastair Hick said. 

 

MiEye Project Lead and Monash University Adjunct (currently at Flinders University) Professor Sean Cain and Professor Jon McCormack from the Faculty of Information Technology are available for interviews. 

 

To learn more about MiEye and submit expressions of interest for the device, please visit: https://www.circadianhealth.com.au/mieye 

- ENDS -

 

MEDIA ENQUIRIES 

Professor Sean Cain M: +61 467 387 031 E: [email protected] 

Professor Jon McCormack M: +61 412 682 136 E: [email protected] 

 

For more Monash media stories, visit our news and events site

More from this category

  • Medical Health Aged Care
  • 17/06/2025
  • 18:41
Ferrer

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

BARCELONA, Spain--BUSINESS WIRE-- Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/Ferrer's pharmaceutical production…

  • Contains:
  • Education Training, Medical Health Aged Care
  • 17/06/2025
  • 11:55
SUADA PR

Applications have just opened for the 2025 First Nations Cancer Scholarship Program

MEDIA RELEASE Applications Open for $5.9 Million First Nations Cancer Scholarship Fund Supporting Indigenous leadership in cancer care and research Tuesday, 17 June 2025 Aurora Education Foundation, in partnership with Cancer Australia, is now accepting applications for the 2025 round of the First Nations Cancer Scholarships, a $5.9 million program supporting Aboriginal and Torres Strait Islander leadership in cancer control. Funded by the Australian Government through Cancer Australia, the Scholarship provides up to $120,000 per year up to three years, as well as academic, wellbeing and community support. It is open to Aboriginal and Torres Strait Islander students, health professionals…

  • Business Company News, Information Technology
  • 17/06/2025
  • 10:38
ASUS Australia

ASUS Republic of Gamers Announces ROG Strix GS-BE18000 WiFi 7 Gaming Router

Featuring wired capacity of 20G via eight ports, two dedicated gaming ports, up to three SSIDs for gaming, IoT device support, VPN support &…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.